Prostate Cancer
Conditions
Brief summary
Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is overexpressed on prostate cancer cells and is well-characterized as an imaging biomarker of prostate cancer. Studies have shown that PSMA PET/CT can detect prostate cancer lesions with excellent contrast and a high detection rate even when the level of prostate specific antigen is low. PSMA imaging is considered the gold standard in imaging of biochemical recurrence, with detection rate of recurrence in 79.5% of patients, in the largest series of 1007 patients. Despite these excellent results, there remains approximately 20% of patients in whom the site of biochemical recurrence cannot be identified and further research is needed into improving detection rates. Androgen deprivation therapy (ADT), represents the standard of care treatment for most men with a rising serum PSA and no evidence of disseminated disease on imaging modalities. There has been some preliminary data that imaging patients early after initiation of ADT therapy may increase detection rates of recurrence sites. The objective of this study is to evaluate if prostate cancer patients with biochemical recurrence and negative PSMA PET/CT can demonstrate in-vivo upregulation of PSMA receptors in an attempt to improve detection rates of recurrent prostate cancer. Patients who are started on ADT when clinically indicated, will have repeat PSMA PET/CT at 4 weeks following initiation of ADT therapy.
Interventions
DIAGNOSTIC_TESTPSMA PET/CT
Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
Sponsors
Jewish General Hospital
Study design
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male sex * Age 18 years or older * Previous diagnosis of prostate cancer following radical prostatectomy or primary radiation therapy, with biochemical recurrence. * Prior negative PSMA PET/CT within 2 months prior to study entry * ECOG performance status 0 - 3, inclusive * Able to understand and provide written informed consent * Initiation of androgen deprivation therapy within 5 weeks prior to study PSMA PET/CT * Able to tolerate the physical/logistical requirements of a PET/CT scan
Exclusion criteria
* Medically unstable patients * Patients who exceed the safe weight limit of the PET/CT bed (200 kg) or who cannot fit through the PET/CT bore (70 cm diameter) * Patients with unmanageable claustrophobia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection rates of recurrence | 2 years | The percentage of 18F-DCFPyL PET/CT positive for identification of biochemical recurrence sites in patients with prostate cancer following initiation of ADT therapy. |
Countries
Canada
Outcome results
None listed